Cancers with a high mutational burden (concept of “altered self”) appear more likely to respond to checkpoint inhibitors. In particular, tumors are more likely to respond if they have neoantigens with high recognition potential, which describes the likelihood that a neoantigen will be presented by MHC molecules and subsequently recognized by T cells.